Showing 1 - 10 of 513
Persistent link: https://www.econbiz.de/10011430453
This study analyses 1400 research projects of the top 20 R&D-spending pharmaceuticals to identify the determinants of successful research projects. We provide clear evidence that externally sourced projects and projects involving biotechnologies perform better than internal projects and chemical...
Persistent link: https://www.econbiz.de/10011374419
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Patent-based measures are frequently used as indicators in empirical research on innovation and technology as well as on firms' strategies and organizational choices to characterize inventions or, more generally, innovative activities and the technological capabilities of organizations. A clear...
Persistent link: https://www.econbiz.de/10010258420
Patent-based measures are frequently used as indicators in empirical research on innovation and technological change. Currently, there is little evidence as to what extent patent-based indicators relate to product market outcomes. Using a unique dataset that links outcomes from product...
Persistent link: https://www.econbiz.de/10010497622
Persistent link: https://www.econbiz.de/10010429323
Persistent link: https://www.econbiz.de/10009582611
Persistent link: https://www.econbiz.de/10011478054
Patent settlements between originator and generic firms in the pharmaceutical industry have been challenged by antitrust and competition authorities in the U.S. and the EU. Particularly settlements with large "reverse payments" to generic firms raise the concern of collusive behaviour for...
Persistent link: https://www.econbiz.de/10011408141
Persistent link: https://www.econbiz.de/10011411855